Trauma & Deformity was Orthopediatrics’s largest product and service line in fiscal 2025, bringing in $166.30M of $236.35M (70%).
| Product and Service | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trauma & Deformity | $85.06M | $106.78M | $145.13M | $166.30M | |||||||
| Scoliosis | $33.43M | $37.93M | $55.15M | $66.05M | |||||||
| Sports Medicine/Other | $3.81M | $4.02M | $4.45M | $4.00M | |||||||
| Total | $122.29M | $148.73M | $204.73M | $236.35M |
Orthopediatrics brought in $236.35M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 15.4% from $204.73M in fiscal 2024. Trauma & Deformity was the largest at $166.30M (70.4%), ahead of Scoliosis at $66.05M (27.9%) and Sports Medicine/Other at $4.00M (1.7%).
Compared with fiscal 2024, Scoliosis grew 19.8% to $66.05M and Trauma & Deformity grew 14.6% to $166.30M. From fiscal 2022 to 2025, combined revenue from these lines grew from $122.29M to $236.35M, a compound annual growth rate of 24.6%. Trauma & Deformity's share of the total rose from 69.6% to 70.4%.
U.S was Orthopediatrics’s largest region in fiscal 2025, bringing in $186.40M of $236.35M (79%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $92.42M | $111.01M | $161.16M | $186.40M | |||||||
| International | $29.87M | $37.72M | $43.56M | $49.95M | |||||||
| Total | $122.29M | $148.73M | $204.73M | $236.35M |
Orthopediatrics brought in $236.35M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 15.4% from $204.73M in fiscal 2024. U.S was the largest at $186.40M (78.9%), ahead of International at $49.95M (21.1%).
Compared with fiscal 2024, U.S grew 15.7% to $186.40M and International grew 14.6% to $49.95M. From fiscal 2022 to 2025, combined revenue from these regions grew from $122.29M to $236.35M, a compound annual growth rate of 24.6%. U.S's share of the total rose from 75.6% to 78.9%.
Orthopediatrics (KIDS) reports its revenue by product and service and by geography. In fiscal 2025, Trauma & Deformity was its largest product and service line, bringing in $166.30M (70.4% of the total), followed by Scoliosis at $66.05M (27.9%).
Trauma & Deformity was Orthopediatrics' largest product and service line in fiscal 2025, bringing in $166.30M, or 70.4% of the $236.35M total across its three product and service lines.
U.S was Orthopediatrics' largest region in fiscal 2025, bringing in $186.40M, or 78.9% of the $236.35M total across its two regions.
Scoliosis grew faster than Trauma & Deformity in fiscal 2025, up 19.8% from $55.15M to $66.05M. Trauma & Deformity grew 14.6% to $166.30M.
Every figure comes from Orthopediatrics' annual financial filings, as reported. Each line keeps the name Orthopediatrics gives it, and years follow its fiscal calendar.
Orthopediatrics' revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.